Criteria for use of filgrastim (granulocyte colony-stimulating factor).
D000970:Antineoplastic Agents / Q000009:adverse effects; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000517:prevention & control; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans
D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor